首页 › 食管腺癌 › 明尼苏达州 › Minneapolis
Minneapolis MN 食管腺癌临床试验
6项针对 食管腺癌的研究正在 Minneapolis及周边约 30 英里内的站点招募参与者。打开研究详情可查看入选标准及联系研究团队的方式。
官方研究文本(英文)
正在为研究招募参与者?将此页面置顶展示 — $99 / 30天 →
Adding Nivolumab to Usual Treatment for People With Advanced Stomach or Esophageal Cancer, PARAMUNE Trial
招募中2/3 期
- Abbott-Northwestern Hospital, Minneapolis
- Park Nicollet Clinic - Saint Louis Park, Saint Louis Park · 距离 5 英里
mFOLFIRINOX Versus mFOLFOX With or Without Nivolumab for the Treatment of Advanced, Unresectable, or Metastatic HER2 Negative Esophageal, Gastroesophageal Junction, and Gastric Adenocarcinoma
招募中3 期
- Abbott-Northwestern Hospital, Minneapolis
- Hennepin County Medical Center, Minneapolis
- Park Nicollet Clinic - Saint Louis Park, Saint Louis Park · 距离 5 英里
Sonesitatug Vedotin in Combination With Capecitabine With or Without Rilvegostomig in Participants With Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma Expressing Claudin18.2
招募中3 期
- Research Site, Minneapolis
A Phase 1 Study of NRM-823 in Participants With Locally Advanced or Metastatic Refractory Solid Tumors
招募中1 期
- Normunity Investigational Site, Minneapolis
A Study to Evaluate the Efficacy and Safety of Ifinatamab Deruxtecan (I-DXd) in Subjects With Recurrent or Metastatic Solid Tumors (IDeate-PanTumor02)
招募中1/2 期
- M Health Fairview University of Minnesota Medical Center, Minneapolis
A Study of Sigvotatug Vedotin in Advanced Solid Tumors
招募中1 期
- Allina Health Cancer Institute - Abbott Northwestern Hospital, Minneapolis
其他城市的 食管腺癌试验
- New York City, NY18 项研究
- Boston, MA13 项研究
- Houston, TX12 项研究
- Arlington, VA11 项研究
- Nashville, TN11 项研究
- Durham, NC10 项研究
- Jacksonville, FL9 项研究
- Rochester, MN9 项研究
- Baldwin Park, CA9 项研究
- St. Louis, MO9 项研究
- Queens, NY9 项研究
- Los Angeles, CA9 项研究
Minneapolis的其他研究
- 非小细胞肺癌27 项研究
- 乳腺癌27 项研究
- 卵巢癌24 项研究
- 前列腺癌23 项研究
- 癌症(所有类型)22 项研究
- 心力衰竭21 项研究
- 急性髓系白血病20 项研究
- 肺癌20 项研究
- 结直肠癌19 项研究
- 子宫内膜癌18 项研究
- 帕金森病17 项研究
- 心血管疾病15 项研究
数据来自 ClinicalTrials.gov,检索日期:2026年10月6日。每项研究自行设定入选标准,由研究团队决定谁能参与。